Cargando…
What’s new in the management of adult bronchiectasis?
Bronchiectasis is a heterogeneous, chronic condition with many aetiologies. It poses a significant burden on patients and healthcare practitioners and services. Clinical exacerbations often result in reduced quality of life, increased rate of lung function decline, increased hospitalisation, and mor...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399954/ https://www.ncbi.nlm.nih.gov/pubmed/28491293 http://dx.doi.org/10.12688/f1000research.10613.1 |
_version_ | 1783230737354326016 |
---|---|
author | Koser, Usma Hill, Adam |
author_facet | Koser, Usma Hill, Adam |
author_sort | Koser, Usma |
collection | PubMed |
description | Bronchiectasis is a heterogeneous, chronic condition with many aetiologies. It poses a significant burden on patients and healthcare practitioners and services. Clinical exacerbations often result in reduced quality of life, increased rate of lung function decline, increased hospitalisation, and mortality. Recent focus in respiratory research, guidelines, and future management options has improved this clinical field in evidence-based practice, but further work and phase III clinical trials are required. This article aims to summarise and explore advances in management strategies in recent years and highlight areas of research and future focus. |
format | Online Article Text |
id | pubmed-5399954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | F1000Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-53999542017-05-09 What’s new in the management of adult bronchiectasis? Koser, Usma Hill, Adam F1000Res Review Bronchiectasis is a heterogeneous, chronic condition with many aetiologies. It poses a significant burden on patients and healthcare practitioners and services. Clinical exacerbations often result in reduced quality of life, increased rate of lung function decline, increased hospitalisation, and mortality. Recent focus in respiratory research, guidelines, and future management options has improved this clinical field in evidence-based practice, but further work and phase III clinical trials are required. This article aims to summarise and explore advances in management strategies in recent years and highlight areas of research and future focus. F1000Research 2017-04-20 /pmc/articles/PMC5399954/ /pubmed/28491293 http://dx.doi.org/10.12688/f1000research.10613.1 Text en Copyright: © 2017 Koser U and Hill A http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Koser, Usma Hill, Adam What’s new in the management of adult bronchiectasis? |
title | What’s new in the management of adult bronchiectasis? |
title_full | What’s new in the management of adult bronchiectasis? |
title_fullStr | What’s new in the management of adult bronchiectasis? |
title_full_unstemmed | What’s new in the management of adult bronchiectasis? |
title_short | What’s new in the management of adult bronchiectasis? |
title_sort | what’s new in the management of adult bronchiectasis? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399954/ https://www.ncbi.nlm.nih.gov/pubmed/28491293 http://dx.doi.org/10.12688/f1000research.10613.1 |
work_keys_str_mv | AT koserusma whatsnewinthemanagementofadultbronchiectasis AT hilladam whatsnewinthemanagementofadultbronchiectasis |